Dacarbazine 100mg/20mL
        
            
            
                | Product Overview | 
                        | Generic Name | Dacarbazine 100mg/20mL | 
                                    | Brand Name(s) | DTIC‑Dome; Bazipar; Cedcozine; Dacarba; Dacarex; Dacin; Dacmed; Darbazine; Dazine; | 
                                    | Form | Powder for injection (IV) | 
                                    | Strength | 100 mg | 
                                    | Therapeutic Class | Chemotherapy (Melanoma, Hodgkin’s lymphoma); second-line soft tissue sarcoma | 
                                    | ATC Code | L01AX03 | 
            
            
            
                | Manufacturing & Regulatory | 
                        | Manufacturer | Faulding Pharmaceuticals Plc (UK); generic producers: Alkem, Intas, | 
                                    | Country | India/USA/EU | 
                                    | GMP Compliance | GMP-certified | 
                                    | DMF/CEP | Type II DMFs | 
                                    | COFEPRIS | Under Registration (2025) | 
                                    | Free Sale Certificate | Available from supplier on request | 
            
            
            
                | Logistics & Export | 
                        | MOQ | 10 Vials | 
                                    | Shelf Life | 24–36 months standard for powder vials | 
                                    | Storage | Store = 25 °C, protect from light | 
                                    | Incoterms | EXW/FOB/CIF negotiable | 
                                    | Lead Time | 7 - 10 Business Days | 
            
            
            
                | Documentation | 
                        | Certificate of Analysis (COA) | Provided per batch | 
                                    | SDS | Manufacturer provides standard SDS (biologic/aqueous injectable) | 
                                    | CTD Summary | Available from manufacturer/distributor under confidentiality | 
            
        
                    
                
Description
                Indicated for metastatic melanoma (single‑agent) and Hodgkin’s disease (combo regimens, e.g., ABVD); category L01AX03 – alkylating agent. “Dacarbazine is an intravenous alkylating agent used as single-agent therapy in metastatic malignant melanoma and as part of combination chemotherapy (e.g., ABVD regimen) for Hodgkin’s disease. It acts through DNA cross-linking and purine analog interference, reducing tumor proliferation
COFEPRIS APPROVAL TO: Mac-Chem Products (India) Pvt. Ltd.            
        
       
            Request for Quote